Genentech, a member of the Roche Group announced that it will showcase 46 abstracts, including 12 oral presentations, from its industry-leading hematology portfolio at the 67th American Society… read more.
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new and updated data for CAR T-cell therapy candidate, GLPG51011, at the 67th American Society of… read more.
Teva Pharmaceutical Industries Ltd. entered into a license agreement with Prestige Biopharma, for the commercialization of Tuznue (trastuzumab), a biosimilar to Herceptin, across a majority of European markets…. read more.
Women living in parts of the United States with lower air quality, especially neighborhoods with heavy emissions from motor vehicles, are more likely to develop breast cancer, according… read more.
Pfizer Inc and Astellas announced final overall survival (OS) results from the Phase III EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as monotherapy, in men with… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Breyanzi. The marketing authorisation… read more.
Eli Lilly and Company announced results from the primary overall survival (OS) analysis of the Phase III monarchE trial showing that two years of adjuvant Verzenio plus endocrine… read more.
Researchers report success in using pazopanib to treat young patients diagnosed with deadly Ewing’s sarcoma. They published their findings on Oct. 23, 2025 in Frontiers in Oncology As… read more.
Lung cancer screening might be the best-kept secret in health care today. Only about 16 percent of those who are eligible in the U.S. get screened for lung… read more.
Researchers report that overall survival is significantly longer among prostate cancer patients at high-risk of biochemical recurrence who are treated with combination enzalutamide and leuprolide rather than with… read more.
Nuvectis Pharma Inc, a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,… read more.
Actinium Pharmaceuticals, Inc.), a leader in the development of differentiated targeted radiotherapies announced that the first-ever preclinical data from its ATNM-400 program in non-small cell lung cancer (NSCLC)… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
